Targeted Delivery of Cancer Drugs Such as Docetaxel (Taxotere).

An August 11th, 2013 blog (below) on this website described how a chemotherapeutic drug such as docetaxel (taxotere) used in the treatment of advanced prostate cancer could be administered more effectively and with less side effects. Taxotere is a variant of an anti-cancer drug (taxol) originally isolated from yew plants.

Nanoparticles are chemical species which can serve as a targeted delivery system for drugs, proteins and other therapeutics. The drug to be delivered is contained within the nanoparticle whose surface is then coated with targeting moieties such as antibodies. The overall result is the delivery of a specific drug directly to the cancer cells thereby allowing for higher localized doses and minimized systemic side effects. This type of delivery system for docetaxel (taxotere) is given as an example in a video and accompanying article from the July 31st, 2013 issue of the Prostate Cancer Foundation NewsPulse. Docetaxel is a chemotherapy used in metastatic, hormone-refractory prostate cancer patients. While it is efficacious, it also can produce serious side effects. It is also limited in the amount of drug which can be administered intravenously. Therefore, nanoparticle delivery can be much more efficacious.

Now in the October 31st, 2013 issue of the Prostate Cancer Foundation (PCF) NewsPulse, the nanoparticle delivery system for docetaxel (taxotere) which specifically targets cancer cells is described and illustrated in more detail. This technology allows higher doses to be administered and reach the tumor with fewer side effects for the patient. This targeted taxotere delivery system (called BIND-014) is being developed by BIND Therapeutics and is currently in Phase II clinical trials in men with treatment-resistant, metastatic prostate cancer and non-small cell lung cancer. BIND-014 specifically targets an antigen called prostate-specific membrane antigen (PSMA) found on the membranes of prostate cancer cells as well as on blood vessels within tumors that feed cancer cells. Details of the current Phase II clinical trial of BIND-014 are discussed in the NewsPulse article.

One thought on “Targeted Delivery of Cancer Drugs Such as Docetaxel (Taxotere).”

  1. Dr. Tony Blau of Seattle’s UW and a consortium called the Center for Cancer Innovation has brought together competing medical systems, patients and advanced science to help target therapy as specific patient’s cancer mutations while freely sharing results and information. I believe this approach has high potential. Check out this interveiw with Dr. Blau: http://drpullen.com/cancercar-redefiningbestcando

Leave a Reply

Your email address will not be published. Required fields are marked *